When Canada legalized a certain controversial mental health treatment, many people were shocked1 2…
It could get rid of antidepressants.
It could eliminate the need for traditional therapy.
There may no longer be months of “talking about your feelings” with a counsellor.
What’s REALLY great is you could relieve depression with 4 TIMES more efficacy than old-school medication.3
It’s safer, cheaper, and has fewer intense side effects.
Many veterans in case studies have quickly gotten over PTSD with this exact method.4 5
And one recent success story is Eric Bjarnason, a retired fireman, who described how he “purged” himself of depression after only one session.6
Given this treatment is filling the big mental health gap left by Big Pharma, it’s obvious why it’s estimated to be…
“A New $100 Billion Market!”7
What’s this breakthrough the Canadian government is backing?
Surprisingly, it’s the use of psychedelics in therapy.
Yes, we’re talking about “drugs” like magic mushrooms (psilocybin), LSD, and ketamine —
The kind people usually associate with “hippies” and party animals.
But with psychedelics now proven by science to be the next Holy Grail in mental health…
… there has been a strong legal push to incorporate them into clinical settings, especially in Canada and the U.S. states of New York and California.89
And taking center stage in this $100 billion revolution is a biotech company called Numinus Wellness Inc. (TSX:NUMITSX:NUMI).
It’s the first publicly-traded company to receive a license from Health Canada for the cultivation and research of psilocybin mushrooms, with…
- 5 approved treatment clinic (1 in Vancouver, 1 in Toronto, 3 in Montreal, and likely 6 more to open in 2022)
- 2 research facilities staffed with scientists, doctors, and other health professionals
- Plans to expand into the U.S.
Turns out, there’s truth in street-claims about psychedelics’ healing power after all…
If you’re skeptical about the idea of psychedelics, then get this:
There’s a giant non-profit called Multidisciplinary Association For Psychedelics Studies (MAPS).
It was founded in 1986 to discover marijuana’s and psychedelics’ medical benefits, and it has raised over $130 million for their research and education!10
As you may know, organizations like this have been responsible for the legal progression of cannabis for decades.
Obviously, cannabis stocks are now beyond speculation, as many of them are heading for the moon.
And investors who thought “drugs can never be legal or medicine” are now left behind.
This is why…
History Could Be About To Repeat Itself With Psychedelics
…given MAPS, one of the most prominent organizations in the space, beginning to sponsor one of Numinus Wellness’s clinical trials on January 19th, 2022.11
The result is the company can now – besides psilocybin – enroll people in MDMA-assisted psychotherapy for PTSD, which is unprecedented!
But saying that psychedelic stocks will be as big as cannabis undermines the potential of this “mental health revolution.” — take a look at this quote from CNBC:
Yes, even “Mr. Wonderful,” the highly-picky investor, thinks psychedelics are bigger than the cannabis wave that came before, which is why he invested in MindMed and Compass Pathways13, two other psychedelic companies…
… and why PayPal billionaire Peter Thiel backed ATAI Life sciences, a similar firm.14
Clearly, investors are willing to put their hard-earned cash into this promising field.
And the good news is that putting Numinus on your watchlist could be equally profitable as when Kevin O’Leary and Peter Thiel invested in other psychedelic companies.
It’s because Numinus Wellness Inc. (TSX:NUMITSX:NUMI) has a strong scientific background, relationships with regulators, treatment services, and state-of-the-art labs for research and testing, which have helped the company record a 245% year-over-year revenue growth as of Q1 of 2022!15
So, it makes sense to hold this undervalued stock than its peers’ before the word spreads.
Here’s why more investors could be attracted to Numinus:
Unique Two-Pronged Business Strategy
Already, Numinus has paved the way for the psychedelics industry through several significant firsts thanks to its powerful, multi-pronged business strategy that includes:
1. NUMINUS BIOSCIENCE:
It is the first public company to complete a legal harvest of psilocybe mushrooms (or ‘magic mushrooms’) and is among the first licensed to handle a variety of psychedelic substances such as ketamine, LSD, mescaline, N,N-Dimethyltryptamine (DMT), N-Methyl-3,4, methylenedioxyamphetamine (MDMA), psilocin, and psilocybin.
Numinus Wellness Inc. (TSX:NUMITSX:NUMI) received amendments on March 4, 2021, that bolstered its federal license, allowing the company to possess, formulate, produce, assemble, sell, import-export, deliver and distribute psychedelics.16
These new license amendments not only place the company at the forefront of global psychedelics research, but it also establishes Numinus’s supplier status for mushroom spores and tissue culture to other licensed dealers, as well as doubled the company’s admissible psilocybin production to 1 kilogram.
On March 9, 2021, Numinus announced plans on March 9 to expand its existing psychedelics research laboratory by 7,500 square feet.
This includes equipping the lab with $1.2 million worth of next-generation analytical equipment such as the Orbitrap Exploris 120 Mass Spectrometer, a high-resolution mass spectrometry instrument.
Numinus Wellness has continued to churn out positive results from its Health Canada licensed laboratory, and is making huge strides already in 2022.
On January 14th, 2022, the company applied to Health Canada for a Phase 1 study, called HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01.17
This is significant because, by creating a “mushroom extract” that is shelf–stable, has proven bioavailability, and can be packaged easily, Numinus Wellness Inc. (TSX:NUMITSX:NUMI) can likely expand the scalability of its treatment clinics, and advance its product development pipeline so it can eventually reach mass retailers.
Imagine the first generation of commercial mushrooms on shelves everywhere, just like you see packaged cannabis of all types in stores in Canada and American states where it is legal.
Numinus has made notable progress in treating PTSD through compassionate access trials for psychedelics-assisted therapy as well as in advancing a compassionate access trial for Psilocybin-Research Intervention with Motivational Enhancement (PRIME) to treat substance use disorders.
The psychedelics-assisted therapy for PTSD, which is in collaboration with MAPS, is the first of its kind in Canada.
MAPS is the leading developer of MDMA-assisted therapy training programs, treatment protocols, and research. When Health Canada approved the MAPS-sponsored open-label safety study evaluating MDMA-assisted therapy for PTSD, it gave both companies a huge boost.18
MAPS founder Rick Doblin speculates that psychedelics and psychedelic-assisted therapies will penetrate mainstream culture by 2070,19 but with the progress MAPS is making now, and getting a “No Objection” letter from Health Canada, it seems like that timeline needs to be pushed up.
MAPS leads the pack of non-profits in the psychedelic space, and it has a clear R&D strategy to make it happen.
In February 2021, the company advanced the trial and transitioned into the pre-implementation stage at Numinus’s Vancouver clinic after completing several milestones, including the recruitment of top-notch therapists, physicians, and staff in preparation for participant enrolment and the ultimate analysis of therapy outcomes.20
Numinus Wellness Inc. (TSX:NUMITSX:NUMI) has also made serious headway in its single-arm, open-label compassionate access trial of PRIME for substance use disorders, which is in collaboration with Syreon. The PRIME study, which is currently in the development stage, will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.
2. NUMINUS HEALTH:
Having started with a clinic in Vancouver and expanded with Mindspace, Numinus Wellness now offers virtual and in-person treatments in 5 clinics across Canada.
Practitioners at Numinus’s Quebec-based clinic currently offer psychedelics-assisted psychotherapy, which can be prescribed to address treatment-resistant depression.
Meanwhile, the company’s Vancouver clinic is conducting two compassionate trials that are open to all Canadians:
- Psychedelics-assisted psychotherapy for PTSD, in collaboration with psychedelic research and advocacy pioneer MAPS (Multidisciplinary Association for Psychedelic Studies)
- Psilocybin-assisted psychotherapy for substance use disorders
Strong Financial Backing
Numinus Wellness Inc. (TSX:NUMITSX:NUMI) went public in 2020 after raising an initial $10 million with institutional support from Canaccord Genuity and Eight Capital.
After listing on the TSX-Venture exchange, Numinus Wellness ended 2020 with oversubscribed financing, raising an additional $17 million.
But that’s not all – on March 19, 2021, the company closed a $40 million bought deal financing, pushing the total treasury balance up to nearly $65 million!21
With its two revenue streams, it is obvious why the company ended Q1 2022 with a strong cash position of $53.9 million while clocking in 245% revenue growth year-over-year!22
And it’s little wonder why Numinus was the Horizons Psychedelic Stock Index ETF’s (PSYK) top-weighted holding at 9.89% on January 27, 2021, the date of the ETF’s debut launch.23
- Favorable Regulatory Landscape – The popularity of psychedelics is soaring. Both the Canadian and US governments are changing laws and regulations regarding their use. Psychedelics have already been decriminalized in US cities like Denver, Oakland, Santa Cruz, and Somerville, while psilocybin has been legalized in Oregon for therapeutic purposes. Canada is also well on its way to decriminalizing.
- Healthcare is Failing Those With Mental Illness – Current statistics say 971 million people worldwide suffer from mental disorders. In Canada, one out of two Canadians is affected by mental health issues by 40. Psychedelics have shown great promise in treating mental disorders.
- Massive New Market Opportunity is Being Created – With the addressable market for mental health now surpassing $100 billion, psychedelics have the opportunity to create a new solution to a growing global problem. In other words, the profit potential for psychedelics is huge!
- The Company Has First Mover Advantage – Numinus Wellness is the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms! The company also possesses a dealer’s license from Health Canada to possess, produce, assemble, sell, import, export, deliver, and distribute LSD, ketamine, MDMA, psilocybin, psilocin, DMT, and mescaline.
- It Has Strong Leadership & R&D Teams – Numinus Wellness is led by scientific, medical, and business leaders with expertise in international healthcare research, policy reform, regulatory affairs, capital markets, technology, and government relations. With their extensive market knowledge, they can avoid potential landmines and find the best route to success.
- The Company Has Gotten Off to a Great Start – Numinus Wellness is already generating revenue, and it is the first public company to complete a legal harvest of psilocybe mushrooms. It now has plans to develop its own psilocybin products later this year!
All of these reasons and more are why institutional money is starting to back Numinus.
Another Factor in Numinus’s Favor – the Increased Attention Being Paid to Mental Health & Substance Abuse
The recent global lockdown brought more attention to mental health and substance abuse, which is not going away once the crisis ends.
Truth is, mental illness has reached crisis proportions and psychedelics are emerging as a new category of medicine that shows promise.
That’s why governments are easing restrictions and allowing for compassionate use in cases like Numinus Wellness Inc. (TSX:NUMITSX:NUMI) clinical trials (more on them later).
Plus, there’s growing support from scientists who are studying this new class of drugs.
A first of its kind research center at Imperial College in London has been studying how drugs such as LSD, psilocybin, DMT, and MDMA impact the brain, and how they may be useful in treating disorders like depression.
As yet another example of the growing interest in psychedelics, the John Hopkins School of Medicine opened a Center for Psychedelic and Consciousness Research in Baltimore in 2019 .
It is studying psilocybin as a treatment for Alzheimer’s disease, PTSD, smoking, anorexia, and depression.
Studies also are planned for opioid addiction and post-treatment of Lyme disease. With $17 million in funding from private donors, the facility is the first research center of its kind in the US, and the largest such center in the world.
Not to be left out, Numinus Wellness Inc. (TSX:NUMITSX:NUMI) is also taking a lead role in mental health treatment.
The company is already operating 4 clinics in Vancouver and Montreal and after striking a deal to acquire the Neurology Centre of Toronto (NCT), Numinus plans to create the first centre for excellence in psychedelic neurology. NCT, which is already a fully operational neurology centre with 13 doctors, 8 allied health staff, nurse practitioners and physician assistants, boasted gross revenues of $1 million in 2020.28
Numinus Wellness also recently acquired Mindspace – a full-service well-being company that began as psychology clinic with an evidence-based approach to mental health.
Mindspace boasts primarily PhD-level psychotherapists, while delivering therapy both in-person and virtually.
With these developments, Numinus Wellness can now offer a full range of therapies. Among them are psilocybin-assisted psychotherapy and compassionate access trials for psilocybin and MDMA.
Pending approval of the regulatory change, Numinus also intends to support practitioners through Special Access to psychedelic-assisted therapies for patients with potentially life-threatening conditions.
Clinics are a critical component of Numinus Wellness’ multi-pronged business strategy, as they allow the company to interact directly with clients and build brand awareness. Meanwhile, Numinus continues to innovate, research, and develop new emerging science for the industry.
Currently, Numinus Wellness Inc. (TSX:NUMITSX:NUMI) is undertaking two compassionate access clinical trials for both psilocybin and MDMA, the first of their kind in Canada.
The psilocybin trial, for example, is an open-label clinical trial evaluating and refining best practices for psilocybin-assisted psychotherapy for people with opioid, alcohol, and stimulant addictions.
It’s truly an enormous marketplace, and Numinus Wellness has a first-mover advantage thanks to its ability to cultivate and harvest directly, and then develop new formulas for products in clinical trials.
Not only can Numinus create new innovative products, but by having its dealer’s license, the company also has the ability to import, export, possess, test, and distribute MDMA, psilocybin, psilocin, and DMT.
It’s a massive opportunity, and Numinus Wellness is the ideal candidate for major pharmaceutical companies to form partnerships, hire contract research services, or engage in analytical testing services. The company’s diverse, multidisciplinary approach puts Numinus front and center with its unique offerings.
Two more things giving Numinus Wellness a market advantage are:
2. Its Knowledgeable Leadership Team
Numinus Wellness Inc.’s team consists of a terrific blend of acclaimed scientists, mental health experts, and successful entrepreneurs.
Team members include:
Payton Nyquvest, Co-founder & Chief Executive Officer Executive – 15+ years in Canada/US capital markets, including raises for early cannabis. Raised $100M+ for public and private companies across North America. Former VP and Head of Sales of one of Canada’s largest independent brokerages.
Dr. Evan Wood, MD, PhD Chief Medical Officer – Research leader on addiction medicine and driver of major health policy reform. Contributed to international guidelines on treatment of HIV in substance users; establishment of Canada’s first supervised injecting site and standards of care; legalization of adult hemp use; and national clinical therapeutic guidelines for multiple substance use disorders. Former Tier 1 Canada Research Chair, UBC Professor of Medicine, founding Executive Director of BC Centre on Substance Use. Published 500+ scientific articles.
Michael Tan, MBA Chief Operations Officer – 20+ years’ operations leadership driving business transformation for global companies, including Indigo, Hudson’s Bay, UPS, and Saks Fifth Avenue. Launched province-wide recreational cannabis operations in BC as founding executive Director of the BC Liquor Distribution Branch-Cannabis Division.
John Fong, CPA Chief Financial Officer – 15+ years building global financial operations for private and public companies (TSX-V, NYSE, London AIM, Lima SE), with experience across mining & resources and technology. Led a precious metals company from exploration to commercial production in 3 years, with net income of $100M and operating cash flow of $98M.
- Prolific Investors Entering the Market – Peter Thiel, the founder of Paypal and Palantir, has invested in psychedelics, along with Kevin O’Leary and Bruce Linton.
- Regulatory Changes Happening Fast – Just like what happened with cannabis in its infancy, psychedelics are gaining momentum as the regulatory policies begin to adapt to the evolving landscape. Canada recently closed its 60-day public commentary period regarding psilocybin and MDMA, and their statements are imminent.
- Multiple Revenue Streams – Numinus has a multi-pronged profit strategy that encompasses two different market segments and provides the company with a diversified and synergistic approach to success.
- Health Canada-Licensed Lab – It’s the first public company with a license to cultivate and harvest psilocybin for research and development. Future products are planned.
- Strong Financial Footing – It has approximately $65 million in cash in the bank to execute its business milestones.
- Huge Potential Upside – Numinus has a low market capitalization relative to the total addressable market value ($100 billion). The company was valued at US$97.3 million on February 1, 2022.
- Seasoned Management & R&D Team – The company has a medical team with over 500+ peer-reviewed publications and a management team with a strong capital markets IQ.
- Top ETF Holding – Horizons Psychedelic Stock Index ETF (PSYK), the first Psychedelic ETF, listed Numinus Wellness Inc. (TSX:NUMI, OTCQX:NUMIF) as its largest holding at 9.89% on the date of the ETF’s launch on January 27, 2021.
1 https://globalnews.ca/news/8514429/psychedelic-drugs-therapy-canada/
2 https://www.benzinga.com/markets/cannabis/22/01/24913445/breaking-canada-opens-new-legal-pathways-for-access-to-psychedelics-treatment-with-psilocybin-an
3 New Investor Deck Slide 5
4 https://www.healthline.com/health-news/how-psychedelic-drugs-are-helping-veterans-and-others-with-ptsd-depression
5 https://maps.org/news/media/the-veteran-psychedelics-for-ptsd-what-a-long-strange-trip-it-s-been/
6 https://toronto.citynews.ca/2021/01/21/retired-firefighter-claims-a-psychedelic-drug-saved-his-life/
7 Original Investor Deck Slide 7
8 https://www.google.com/url?q=https://www.sacbee.com/news/politics-government/capitol-alert/article250445971.html&sa=D&source=docs&ust=1643238412250471&usg=AOvVaw2eCF4he5H6-Dk9UiJV9qWf
9 https://globalnews.ca/news/8514429/psychedelic-drugs-therapy-canada/
10 https://maps.org/about-maps/#history
11 https://www.newswire.ca/news-releases/numinus-announces-key-milestones-in-maps-sponsored-mdma-assisted-therapy-for-ptsd-clinical-trial-879526713.html
12 https://www.cnbc.com/2021/05/11/kevin-oleary-psychedelic-drugs-far-exceed-cannabis-potential.html
13 https://www.cnbc.com/2021/05/11/kevin-oleary-psychedelic-drugs-far-exceed-cannabis-potential.html
14 https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html
15 https://www.newswire.ca/news-releases/numinus-wellness-inc-reports-q1-2022-results-824217004.html
16 https://numinus.ca/investors/news-release/regulatory-approvals-place-numinus-lab-at-the-forefront-of-global-psychedelics-research
17 https://www.investors.numinus.com/news/news-details/2022/Numinus-Submits-Clinical-Trial-Application-for-Phase-1-Trial-on-Proprietary-Psilocybin-Product/default.aspx
18 https://www.newswire.ca/news-releases/numinus-announces-health-canada-approval-of-maps-sponsored-open-label-study-for-mdma-assisted-therapy-for-ptsd-864100377.html
19 https://www.gq.com/story/rick-doblin-interview-where-the-psychedelic-revolution-is-headed/amp
20 https://tinyurl.com/c79yusjy
21 https://www.stockwatch.com/News/Item/Z-C!NUMI-3050672/C/NUMI
22 https://www.newswire.ca/news-releases/numinus-wellness-inc-reports-q1-2022-results-824217004.html
23 https://www.horizonsetfs.com/horizons/media/pdfs/productsheets/PSYK-Product-Sheet.pdf
24https://mindmed.co/news/press-release/mindmed-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-project-lucy
25https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/
26https://www.globenewswire.com/news-release/2020/08/18/2079824/0/en/Mydecine-Launches-World-s-First-Natural-Sourced-cGMP-Psilocybin-for-Global-Research-Sales-and-Distribution-Enterprise.html
27 https://www.joplinglobe.com/region/national_business/cybin-granted-dea-schedule-i-manufacturing-license/article_6237bcb6-b54f-5cac-808d-13ead651208f.html
28 https://numinus.com/news/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology/
IMPORTANT NOTICE AND DISCLAIMER
This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Numinus Wellness Inc. (“NUMI”) and its securities, NUMI has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by NUMI) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP.
The Publisher does not own any shares of any profiled company NUMI and has no information concerning share ownership by others of in the profiled company NUMI. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
FORWARD LOOKING STATEMENTS.
This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to NUMI industry; (b) market opportunity; (c) NUMI business plans and strategies; (d) services that NUMI intends to offer; (e) NUMI milestone projections and targets; (f) NUMI expectations regarding receipt of approval for regulatory applications; (g) NUMI intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) NUMI expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute NUMI business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) NUMI ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) NUMI ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) NUMI ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of NUMI to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) NUMI operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact NUMI business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing NUMI business operations (e) NUMI may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
INDEMNIFICATION/RELEASE OF LIABILITY.
By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY.
Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:
- The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Numinus Wellness Inc.
SHARE OWNERSHIP
The Website Host does not own any shares of any profiled Numinus Wellness Inc. and has no information concerning share ownership by others of any profiled Numinus Wellness Inc. The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED
The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Numinus Wellness Inc. or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Numinus Wellness Inc. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Numinus Wellness Inc. ’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES
This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY
The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.
FORWARD LOOKING INFORMATION
This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Numinus Wellness Inc. future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Numinus Wellness Inc. industry; (b) market opportunity; (c) Numinus Wellness Inc. business plans and strategies; (d) services that Numinus Wellness Inc. intends to offer; (e) Numinus Wellness Inc. milestone projections and targets; (f) Numinus Wellness Inc. expectations regarding receipt of approval for regulatory applications; (g) Numinus Wellness Inc. intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Numinus Wellness Inc. expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Numinus Wellness Inc. business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Numinus Wellness Inc. ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Numinus Wellness Inc. ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Numinus Wellness Inc. ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Numinus Wellness Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Numinus Wellness Inc. operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Numinus Wellness Inc. business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Numinus Wellness Inc. business operations (e) Numinus Wellness Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
HISTORICAL INFORMATION
Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Numinus Wellness Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Numinus Wellness Inc. or such entities and are not necessarily indicative of future performance of Numinus Wellness Inc. or such entities.
